miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1
- 268 Downloads
Gallbladder cancer (GBC) is the most common malignancy in biliary tract with poor prognosis. Due to its high chemoresistance, systemic chemotherapies have had limited success in treating GBC patients. MicroRNAs (miRNAs) are emerging novel regulators of chemoresistance, which modulate the expression of drug resistance-related genes. In this study, we investigated the association between miR-145 expression and cisplatin sensitivity by both in vivo and in vitro analysis. Quantitative PCR (q-PCR) analysis indicated an increased miR-145 expression in GBC tissues. In addition, studies on GBC cell lines suggested an increased cisplatin efficacy with miR-145 overexpression, whereas decreasing miR-145 expression reduced cisplatin sensitivity. Further, we found that miR-145 accelerated MRP1 mRNA degradation by directly targeting its 3′-UTR and therefore caused increased cisplatin toxicity in GBC cells. Moreover, lower miR-145 and higher MRP1 expression levels predicted poor prognosis in GBC patients who received chemotherapy. Collectively, our findings established a rationale for using miR-145 expression as a biomarker to identify cisplatin-resistant GBC patients and propose that treatment strategies increasing the expression of miR-145 could be a new therapeutic approach for GBC patients.
KeywordsGallbladder cancer miR-145 MRP1 Chemoresistance Cisplatin
This work was supported by the National Science Foundation of China (81072011, 81272748, and 81472240), National Key Technology R&D Program (2012BAI06B01), Foundation of Science and Technology Commission of Shanghai Municipality (12XD1403400), and Foundation of Shanghai Municipal Health Bureau (XBR2011035).
Compliance with ethical standards
Conflicts of interest
- 11.Ge G, Zhou C, Ren Y, Tang X, Wang K, Zhang W, et al. Enhanced slc34a2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via slc34a2-bmi1-abcc5 signaling. Tumour Biol. 2015Google Scholar
- 12.Liang X, Xu X, Wang F, Li N, He J. E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1alpha contributes to multicellular resistance in colorectal cancer. Tumour Biol. 2015.Google Scholar
- 15.Sicchieri RD, da Silveira WA, Mandarano LR, Goncalves de Oliveira TM, Carrara HH, Muglia VF, et al. Abcg2 is a potential marker of tumor-initiating cells in breast cancer. Tumour Biol. 2015.Google Scholar
- 32.Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, et al. Inhibition of microrna-196a might reverse cisplatin resistance of a549/ddp non-small-cell lung cancer cell line. Tumour Biol. 2015.Google Scholar
- 35.Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, et al. Stromal expression of mir-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2015.Google Scholar